Androgens and COVID-19

Overview

Journal J Cosmet Dermatol

Specialty Dermatology

Date 2022 May 16

PMID 35576054

Authors

Kinnor Das

Anant Patil

Andy Goren

Clay J Cockerell

Mohamad Goldust

Affiliations

Soon will be listed here.

Abstract

Background: The humans have been disproportionately affected by the coronavirus disease (COVID-19) pandemic. The novel coronavirus or the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) causing coronavirus disease (COVID-19) has spread across the globe. Androgens have been suggested to have a role in COVID-19 pathogenesis.

Objective: The objective of this review article is to study the link between androgens and COVID-19.

Methodology: PubMed and Google Scholar search was performed to retrieve literature related to the topic. Review articles, clinical trials, retrospective studies, observational studies, and case-control studies were considered for the review.

Results: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected men are more inclined to be hospitalized for intensive care unit (ICU) as compared with women. This difference in the ICU admissions provides some clue for possible influence of androgens in the severity of COVID-19. The contribution of androgen and androgen receptor in COVID-19 disease and its severity, as well as the numerous medications targeting androgen and its receptor for lowering COVID-19 disease severity, are discussed in this review. Available literature suggests the role of androgen in the pathogenesis and severity of COVID-19. Sensitivity for androgen may be an important factor in regulating the severity of COVID-19 disease.

Conclusion: There is a scope for the development of COVID-19 treatments based on androgen suppression. Clinical trials may furnish pivotal data and add more evidence-based options for the management of COVID-19.

Citing Articles

Insights into the Scenario of SARS-CoV-2 Infection in Male Reproductive Toxicity.

Mukherjee A, Wanjari U, Gopalakrishnan A, Kannampuzha S, Murali R, Namachivayam A Vaccines (Basel). 2023; 11(3).

PMID: 36992094 PMC: 10054059. DOI: 10.3390/vaccines11030510.

The relationship between sex steroids (E2, progesterone, and AMH) levels and severity and fatality of COVID-19: A systematic review.

Qaderi K, Hosseinirad H, Kalhor M, Zangeneh S, Pournaghi M, Khodavirdilou R Heliyon. 2023; 9(3):e14218.

PMID: 36873532 PMC: 9974207. DOI: 10.1016/j.heliyon.2023.e14218.

Androgens and COVID-19.

Das K, Patil A, Goren A, Cockerell C, Goldust M J Cosmet Dermatol. 2022; 21(8):3176-3180.

PMID: 35576054 PMC: 9348029. DOI: 10.1111/jocd.15090.

References

Ansarin K, Tolouian R, Ardalan M, Taghizadieh A, Varshochi M, Teimouri S . Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. Bioimpacts. 2020; 10(4):209-215. PMC: 7502909. DOI: 10.34172/bi.2020.27. View

Wambier C, Vano-Galvan S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard A . Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020; 83(2):680-682. PMC: 7242206. DOI: 10.1016/j.jaad.2020.05.079. View

Mohamed M, Moulin T, Schioth H . Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine. 2020; 71(1):3-8. PMC: 7657570. DOI: 10.1007/s12020-020-02536-6. View

Morgentaler A, Khera M, Maggi M, Zitzmann M . Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014; 11(7):1636-45. DOI: 10.1111/jsm.12546. View

Baldassarri M, Picchiotti N, Fava F, Fallerini C, Benetti E, Daga S . Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine. 2021; 65:103246. PMC: 7908850. DOI: 10.1016/j.ebiom.2021.103246. View

Bobjer J, Katrinaki M, Tsatsanis C, Lundberg Giwercman Y, Giwercman A . Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One. 2013; 8(4):e61466. PMC: 3630214. DOI: 10.1371/journal.pone.0061466. View

Lu N, Wardell S, Burnstein K, DeFranco D, Fuller P, Giguere V . International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 2006; 58(4):782-97. DOI: 10.1124/pr.58.4.9. View

Giovannucci E, Stampfer M, Krithivas K, Brown M, Dahl D, Brufsky A . The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997; 94(7):3320-3. PMC: 20367. DOI: 10.1073/pnas.94.7.3320. View

Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D . Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2020; 9(1):88-98. PMC: 7280645. DOI: 10.1111/andr.12821. View

10.

Lee J, Yousaf A, Fang W, Kolodney M . Male balding is a major risk factor for severe COVID-19. J Am Acad Dermatol. 2020; 83(5):e353-e354. PMC: 7373684. DOI: 10.1016/j.jaad.2020.07.062. View

11.

Maggio M, Basaria S, Ceda G, Ble A, Ling S, Bandinelli S . The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest. 2006; 28(11 Suppl Proceedings):116-9. View

12.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

13.

Das K, Patil A, Goren A, Cockerell C, Goldust M . Androgens and COVID-19. J Cosmet Dermatol. 2022; 21(8):3176-3180. PMC: 9348029. DOI: 10.1111/jocd.15090. View

14.

Lin B, Ferguson C, White J, Wang S, Vessella R, True L . Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999; 59(17):4180-4. View

15.

Cadegiani F, Lim R, Goren A, McCoy J, Situm M, Kovacevic M . Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol Venereol. 2020; 35(2):e101-e104. DOI: 10.1111/jdv.17004. View

16.

Mikkonen L, Pihlajamaa P, Sahu B, Zhang F, Janne O . Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol. 2009; 317(1-2):14-24. DOI: 10.1016/j.mce.2009.12.022. View

17.

Sinha N, Balayla G . Hydroxychloroquine and COVID-19. Postgrad Med J. 2020; 96(1139):550-555. PMC: 10016880. DOI: 10.1136/postgradmedj-2020-137785. View

18.

Muller Ramos P, Ianhez M, Miot H . Alopecia and grey hair are associated with COVID-19 Severity. Exp Dermatol. 2020; 29(12):1250-1252. DOI: 10.1111/exd.14220. View

19.

Goren A, Vano-Galvan S, Wambier C, McCoy J, Gomez-Zubiaur A, Moreno-Arrones O . A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020; 19(7):1545-1547. DOI: 10.1111/jocd.13443. View

20.

McCoy J, Cadegiani F, Wambier C, Herrera S, Vano-Galvan S, Mesinkovska N . 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2020; 35(4):e243-e246. DOI: 10.1111/jdv.17021. View